Advertisement
YOU ARE HERE: LAT HomeCollectionsFixme

California: News and Insight on Business in the Golden
State

Spotlight: ICN Acquires Global Rights to 4 Roche Drugs

October 06, 1998

ICN Pharmaceuticals Inc., moving to offset business setbacks in Eastern Europe, said it's buying global rights to four medicines from Swiss drug giant Roche Holdings for $179 million in cash and stock. Costa Mesa-based ICN is acquiring rights to Dalmodorm, a drug for sleep disorders; Fluoro-Uracil, a treatment for cancer; Librax, for gastrointestinal disorders; and Mogadon, a sleep-disorder drug used to treat epilepsy. The drugs are expected to generate sales of about $67 million a year.

Advertisement
Los Angeles Times Articles
|
|
|